Screening DIVA - Diffuse Vascular Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01076738|
Recruitment Status : Completed
First Posted : February 26, 2010
Last Update Posted : September 13, 2010
To investigate the value of the Edinburgh Claudication Questionnaire (ECQ) against the ankle-brachial index (ABI) in Canadian patients mainly followed in general practice, with documented acute coronary syndrome (ACS)/ischemic stroke (IS)/transient ischemic attack (TIA) and who are not known to have peripheral arterial disease (PAD) at the time of enrolment.
To collect data on the prevalence of PAD in this population as measured by ABI.
|Condition or disease|
|Peripheral Vascular Diseases|
|Study Type :||Observational|
|Estimated Enrollment :||2233 participants|
|Official Title:||The Value of Routine Screening for Diffuse Vascular Disease in the Canadian Post-Acute Coronary Syndrome/Ischemic Stroke/Transient Ischemic Attack General Practice Population With Previously Undocumented Peripheral Arterial Disease|
|Study Start Date :||April 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
|single group study|
- To determine the sensitivity and specificity of the ECQ versus ABI. [ Time Frame: within 12 (+/- 2) weeks ]
- To determine the prevalence of symptomatic PAD (positive ECQ and ABIT <0.9) [ Time Frame: within 12 (+/- 2) weeks ]
- To determine the prevalence of asymptomatic PAD (negative ECQ and ABI <0.9) [ Time Frame: within 12 (+/- 2) weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01076738
|Sanofi-Aventis Administrative Office|
|Study Director:||Medical Affairs||Sanofi|